Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

 Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

Shots:

  • The approval is based on P-III SPARTAN study results assessing Erleada (240 mg,qd) vs PBO in 1,207 patients with NM-CRPC in ratio (2:1) in patients with (NM-CRPC)
  • P-III SPARTAN study results: 72% reduction in risk of distant metastasis or death; mPFS (40.51 mos. vs 16.20 mos.); 24% required number of events
  • Erleada (apalutamide) is an androgen receptor (AR) inhibitor targeted for patients with NM-CRPC

Click here to read full press release/ article | Ref: Janssen | Image: Axios

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post